1. Home
  2. BCAB vs HYFM Comparison

BCAB vs HYFM Comparison

Compare BCAB & HYFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • HYFM
  • Stock Information
  • Founded
  • BCAB 2007
  • HYFM 1977
  • Country
  • BCAB United States
  • HYFM United States
  • Employees
  • BCAB N/A
  • HYFM 286
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • HYFM Industrial Machinery/Components
  • Sector
  • BCAB Health Care
  • HYFM Industrials
  • Exchange
  • BCAB Nasdaq
  • HYFM Nasdaq
  • Market Cap
  • BCAB 22.3M
  • HYFM 16.0M
  • IPO Year
  • BCAB 2020
  • HYFM 2020
  • Fundamental
  • Price
  • BCAB $0.41
  • HYFM $3.73
  • Analyst Decision
  • BCAB Buy
  • HYFM Hold
  • Analyst Count
  • BCAB 2
  • HYFM 2
  • Target Price
  • BCAB $1.00
  • HYFM $7.00
  • AVG Volume (30 Days)
  • BCAB 421.1K
  • HYFM 34.1K
  • Earning Date
  • BCAB 05-06-2025
  • HYFM 05-13-2025
  • Dividend Yield
  • BCAB N/A
  • HYFM N/A
  • EPS Growth
  • BCAB N/A
  • HYFM N/A
  • EPS
  • BCAB N/A
  • HYFM N/A
  • Revenue
  • BCAB $11,000,000.00
  • HYFM $176,650,000.00
  • Revenue This Year
  • BCAB N/A
  • HYFM $5.45
  • Revenue Next Year
  • BCAB N/A
  • HYFM $5.33
  • P/E Ratio
  • BCAB N/A
  • HYFM N/A
  • Revenue Growth
  • BCAB N/A
  • HYFM N/A
  • 52 Week Low
  • BCAB $0.24
  • HYFM $1.50
  • 52 Week High
  • BCAB $2.53
  • HYFM $8.55
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 50.31
  • HYFM 59.27
  • Support Level
  • BCAB $0.37
  • HYFM $3.00
  • Resistance Level
  • BCAB $0.42
  • HYFM $3.91
  • Average True Range (ATR)
  • BCAB 0.04
  • HYFM 0.31
  • MACD
  • BCAB -0.01
  • HYFM 0.01
  • Stochastic Oscillator
  • BCAB 35.88
  • HYFM 79.98

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About HYFM Hydrofarm Holdings Group Inc.

Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.

Share on Social Networks: